Medicinal Cannabis for Gastrointestinal Disorders: Evidence and Recommendations

Join Dr Scott Smid, Senior Lecturer at the University of Adelaide, as we delve into the therapeutic potential of medicinal cannabis in gastrointestinal disorders.

About the Webinar

Join Dr. Scott Smid, Senior Lecturer at the University of Adelaide, as we explore the therapeutic potential of medicinal cannabis in managing gastrointestinal disorders, with a particular focus on inflammatory bowel disease (IBD) and some aspects of irritable bowel syndrome (IBS). These conditions highlight the critical need for effective treatments. Discover how cannabinoids can modulate inflammation and gut motility, potentially enhancing patient outcomes. Gain insights into general dosing strategies and the variety of administration methods, emphasising the importance of patient education in effective cannabinoid therapy. While the session will not provide detailed dosing guidelines for specific GI conditions, it will offer a broad overview informed by Dr. Smid's preclinical research. This approach aims to make complex scientific information accessible, enhancing understanding without diluting the impact of the core topics.

Learning Outcomes

Identify how cannabinoids affect inflammation and gut motility in gastrointestinal disorders like IBD and IBS, improving patient outcomes.
Apply general dosing strategies, administration methods, and the importance of patient education
Analyse current research on medicinal cannabis in gastrointestinal health to guide future therapeutic strategies.

About the speaker

Dr Scott Smid is a pharmacologist specializing in drug discovery and development research both in industry and academia. He maintains a strong research interest in experimental therapeutics applied towards novel treatments for gastrointestinal and neurodegenerative diseases. This includes investigating the biological actions of phytocannabinoids, synthetic cannabinoids and endocannabinoids in areas as diverse as gut function, inflammation and neurodegeneration. Current interests include novel ligand development for binding and inhibiting pathological aggregating proteins such as beta-amyloid and alpha-synuclein, which are associated with Alzheimer's and Parkinson's disease.

On-demand Webinar

Subscribe to our Free Plan and gain access to this on-demand webinar plus four more, at no cost.

Webinar details

Claim 1 CPD hour

1 hour of recorded content

Statement of Attendance

Our Sponsors

Claim 1 CPD Hour

Medihuanna is a CPD approved education provider, and this activity has been approved by the RACGP (Activity ID: 848768). Upon completing this activity, you will be eligible to claim CPD hours. The activity will include the following CPD allocation which will be uploaded to the RACGP dashboard.